Can heat therapy treat depression?
In a 6-week randomized, double-blind trial, whole-body hyperthermia raised the ratio of interleukin-6 to soluble interleukin-6 receptor immediately after treatment, and the size of that rise tracked lower depressive symptoms at weeks 1, 2, 4 and 6. This is a secondary analysis of a single sham-controlled trial in 26 adults with major depressive disorder, not a review of 11 studies, and the numbers below come from that one trial.
A rise in the IL-6 to soluble IL-6 receptor ratio shifts signaling toward the classical, anti-inflammatory interleukin-6 pathway. An earlier secondary analysis from the same trial had already found that whole-body hyperthermia produced an acute and transitory increase in plasma IL-6 without moving other cytokines, including tumor necrosis factor-alpha, IL-1α, IL-1β, IL-4 and IL-8.
What the data show:
- Immediate signal: Active whole-body hyperthermia increased the IL-6:soluble IL-6 receptor ratio only post-treatment, F(3,72)=11.73, p<.001, and not pre-intervention or at weeks 1 and 4
- Symptom link: Increases in that ratio after whole-body hyperthermia were associated with decreased depressive symptoms at weeks 1, 2, 4 and 6 compared with sham, b=-229.44, t=-3.82, p<.001
- Study scope: 338 individuals screened, 34 randomized, 30 received the intervention, 26 contributed at least 2 blood draws and symptom assessments
- Groups analyzed: 12 assigned to whole-body hyperthermia and 14 assigned to sham
The trial itself was published in Brain, Behavior, and Immunity in 2024. Its primary antidepressant outcomes were reported separately in an earlier paper from the same clinical trial; this analysis was designed to ask whether interleukin-6 signaling explains that effect.
Dr. Kumar’s Take
I read this as a mechanism paper, not a treatment recommendation. The interesting part is the direction of the immune finding. Depression research has spent years framing inflammation as the enemy, and here the antidepressant signal tracks an acute rise in an inflammatory cytokine, specifically the shift toward classical interleukin-6 signaling right after the heat exposure. That fits a hormesis model better than a simple anti-inflammation model: a brief, controlled physiologic stress that pushes a system back toward baseline rather than a drug taken every day. I want to be honest about the ceiling on this evidence. Twenty-six people analyzed in a single trial, with the biomarker change detectable only in the window immediately after treatment, is a hypothesis worth pursuing, not a result that changes how I would counsel a patient with depression tomorrow. What would change my mind is replication at a larger scale with the same biomarker measured on the same schedule.
Study Snapshot
This was a 6-week, randomized, double-blind study at a university-based medical center comparing whole-body hyperthermia with a sham condition. Eligible participants were medically healthy adults aged 18 to 65 years who met criteria for major depressive disorder, were free of psychotropic medication, and had a baseline score of at least 16 on the 17-item Hamilton Depression Rating Scale. Allocation was 1-to-1 in blocks of 6. The secondary analysis reported here examined change in the ratio of IL-6 to soluble IL-6 receptor pre-intervention, post-intervention, and at weeks 1 and 4, then used hierarchical linear modeling to test whether an increase in that ratio after treatment was associated with lower depressive symptoms at weeks 1, 2, 4 and 6.
Results in Real Numbers
Of 338 individuals screened, 34 were randomized, 30 received an intervention, and 26 had at least 2 blood draws and depressive symptom assessments and were included in this analysis. Twelve were randomized to whole-body hyperthermia, 75% female, mean age 37.9 years (SD 15.3). Fourteen were randomized to sham, 57.1% female, mean age 41.1 years (SD 12.5).
Compared with sham, active whole-body hyperthermia increased the IL-6 to soluble IL-6 receptor ratio at the post-treatment timepoint only, F(3,72)=11.73, p<.001. The ratio did not differ pre-intervention, and it did not differ at week 1 or week 4, so the biochemical change was confined to the period immediately after the session.
In the hierarchical linear model, the rise in that ratio after whole-body hyperthermia moderated depressive symptoms across follow-up. Larger increases in the IL-6 to soluble IL-6 receptor ratio were associated with greater decreases in depressive symptoms at weeks 1, 2, 4 and 6 in the whole-body hyperthermia group relative to sham, b=-229.44, t=-3.82, p<.001.
The authors frame this as an association within a small secondary analysis. Acute activation of classical interleukin-6 signaling is offered as a candidate mechanism that could be targeted to broaden antidepressant options, not as an established one.
Who Benefits Most
The evidence here speaks to one narrow group: medically healthy adults aged 18 to 65 with major depressive disorder, off psychotropic medication, with at least moderate symptom severity at baseline as measured by a 17-item Hamilton score of 16 or higher. Those are the people who were enrolled, and I would not extend the finding past them.
People taking psychotropic medication, people with significant medical comorbidity, and people outside that age range were not studied, so this trial says nothing about how they would respond. Anyone considering heat-based interventions for mood should treat this as early mechanistic research rather than as a basis for changing an existing treatment plan.
Safety, Limits, and Caveats
The sample is small. Twenty-six analyzed participants, split 12 and 14 across two arms, gives limited precision, and this is a secondary analysis of a trial designed to answer a different primary question. The screening funnel matters too: 338 people were screened to randomize 34, which tells you the enrolled group was selected and healthier than a typical depressed population.
The biomarker effect was detectable only immediately after treatment, with no difference from sham at weeks 1 or 4. A corrigendum to the paper was published in 2025, so anyone citing the numbers should read the corrected version.
Whole-body hyperthermia in this study was delivered in a medical center under supervision. It is not equivalent to a sauna session at home, and heat exposure carries real cardiovascular and hydration risk in people with medical conditions.
Practical Takeaways
- Read this as mechanism research from a single small trial, not as evidence that heat therapy should be used to treat depression
- The candidate mechanism is a shift toward classical interleukin-6 signaling immediately after heat exposure
- The immune change was present only right after treatment, while the symptom association extended to weeks 1, 2, 4 and 6
- Participants were medically healthy adults aged 18 to 65 who were off psychotropic medication, so the findings do not transfer to medicated or medically complex patients
- If you are interested in this approach, the appropriate next step is a conversation with your treating clinician, not self-administered heat exposure
What This Means for Depression Treatment
If acute interleukin-6 signaling turns out to be a genuine antidepressant lever, heat is only one possible way to pull it. That is the value of this paper: it names a measurable pathway that a larger trial can confirm or rule out.
Existing antidepressant treatments are only modestly effective, and depression is the leading cause of global disability, projected to be the greatest contributor to global disease burden by 2030. That gap is why mechanistic leads like this one get pursued, and also why they need to be tested properly before they reach patients.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Cold-Water Immersion: Neurohormesis and Clinical Applications
FAQs
What did this study actually test?
It tested whether activation of the classical anti-inflammatory interleukin-6 pathway is associated with the antidepressant effect of whole-body hyperthermia, using data from a 6-week randomized, double-blind, sham-controlled trial in adults with major depressive disorder.
How large was the study?
Small. Of 338 people screened, 34 were randomized and 26 were included in this analysis, 12 in the whole-body hyperthermia group and 14 in the sham group.
Does this prove heat therapy treats depression?
No. It shows an association between a treatment-induced rise in the IL-6 to soluble IL-6 receptor ratio and lower depressive symptoms at weeks 1, 2, 4 and 6 in a small sample. Confirming that as a treatment mechanism requires larger trials.
Bottom Line
In one small randomized sham-controlled trial, whole-body hyperthermia produced a rise in the IL-6 to soluble IL-6 receptor ratio immediately after treatment, and larger rises were associated with lower depressive symptoms at weeks 1, 2, 4 and 6. Acute activation of classical interleukin-6 signaling is a plausible new antidepressant mechanism worth testing at scale, and nothing more than that yet.
